Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic phase 2 trial of hydroxychloroquine for early COVID-19 in oncohematologic patients and healthcare professionals
2020-001765-37Phase 2Terminated
- Sponsor
- Institut Català d'Oncologia
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Institut Català d'Oncologia. Primary endpoint: Disease control without symptoms at 14 days. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001765-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001765-37.